Assessment of Impact of Human Leukocyte Antigen-Type and Cytokine-Type Responses on Outcomes after Targeted Therapy Currently Used to Treat Chronic Lymphocytic Leukemia
Tumor growth and metastasis are reliant on intricate interactions between the host immune system and various counter-regulatory immune escape mechanisms employed by the tumor. Tumors can resist immune surveillance by modifying the expression of human leukocyte antigen (HLA) molecules, which results...
Main Authors: | Mihaela Andreescu, Nicoleta Berbec, Alina Daniela Tanase |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-04-01
|
Series: | Journal of Clinical Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2077-0383/12/7/2731 |
Similar Items
-
Current and future treatment strategies in chronic lymphocytic leukemia
by: Krish Patel, et al.
Published: (2021-04-01) -
Treatment of Double-Refractory Chronic Lymphocytic Leukemia—An Unmet Clinical Need
by: Przemysław Zygmunciak, et al.
Published: (2024-01-01) -
Combining BTK inhibitors with BCL2 inhibitors for treating chronic lymphocytic leukemia and mantle cell lymphoma
by: Jing Zhang, et al.
Published: (2022-04-01) -
The Role of BTK Inhibition in the Treatment of Chronic Lymphocytic Leukemia: A Clinical View
by: Tambaro FP, et al.
Published: (2021-10-01) -
Natural Killer Cells in Chronic Lymphocytic Leukemia: Functional Impairment and Therapeutic Potential
by: Max Yano, et al.
Published: (2022-11-01)